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Promoter hypermethylation of cancer-related genes: a strong independent
prognostic factor in acute lymphoblastic leukemia
Jose Roman-Gomez, Antonio Jimenez-Velasco, Juan A. Castillejo, Xabier Agirre, Manuel Barrios, German Navarro,
Francisco J. Molina, Maria J. Calasanz, Felipe Prosper, Anabel Heiniger, and Antonio Torres
Promoter hypermethylation plays an im-
portant role in the inactivation of cancer-
related genes. This abnormality occurs
early in leukemogenesis and seems to be
associated with poor prognosis in acute
lymphoblastic leukemia (ALL). To deter-
mine the extent of hypermethylation in
ALL, we analyzed the methylation status
of the CDH1, p73, p16, p15, p57, NES-1,
DKK-3, CDH13, p14, TMS-1, APAF-1,
DAPK, PARKIN, LATS-1, and PTEN genes
in 251 consecutive ALL patients. A total of
77.3% of samples had at least 1 gene
methylated, whereas 35.9% of cases had
4 or more genes methylated. Clinical fea-
tures and complete remission rate did not
differ among patients without methylated
genes, patients with 1 to 3 methylated
genes (methylated group A), or patients
with more than 3 methylated genes (meth-
ylated group B). Estimated disease-free
survival (DFS) and overall survival (OS) at
11 years were 75.5% and 66.1%, respec-
tively, for the nonmethylated group; 37.2%
and 45.5% for methylated group A; and
9.4% and 7.8% for methylated group B
(P < .0001 and P  .0004, respectively).
Multivariate analysis demonstrated that
the methylation profile was an indepen-
dent prognostic factor in predicting DFS
(P < .0001) and OS (P  .003). Our results
suggest that the methylation profile may
be a potential new biomarker of risk pre-
diction in ALL. (Blood. 2004;104:
2492-2498)
© 2004 by The American Society of Hematology
Introduction
Cytogenetic studies in acute lymphoblastic leukemia (ALL) reveal
a wide variety of translocations involving this disease; these
translocations can either (1) deregulate an intact gene by disruption
or removal and replacement of the adjacent controlling elements or
(2) create a new fusion gene.1-2 Chromosome translocation is
clearly an important oncogenic step in ALL, and structurally
altered genes play key roles in cell proliferation, differentiation,
apoptosis, and gene transcription. Although these molecular abnor-
malities may serve as diagnostic and prognostic markers, they are
detectable only at low rates in specific morphologic subtypes of
ALL.1-2 Furthermore, oncogenes and tumor-suppressor genes that
are frequently altered in solid tumors, such as p53 or RAS, are
infrequently mutated in ALL.3 In addition to these genetic changes,
epigenetic silencing of tumor-related genes, due to hypermethyl-
ation, has recently emerged as one of the pivotal alterations in
cancer development.4-6
In the mammalian genome, methylation takes place only at
cytosine bases that are located 5 to guanosine in a CpG dinucle-
otide.4-6 This dinucleotide is actually underrepresented in much of
the genome, but short regions of 0.5 to 4 kb in length, known as
CpG islands, are rich in CpG content. Most CpG islands are found
in the proximal promoter regions of almost half of the genes in the
human genome and are, generally, unmethylated in normal cells. In
cancer, however, the hypermethylation of these promoter areas is
the most well-recognized epigenetic change to occur in tumors; it is
found in virtually every type of neoplasm and is associated with the
inappropriate transcriptional silencing of genes.4-6 Thus, aberrant
methylation serves as an alternative mechanism of gene inactiva-
tion in neoplasia, and surprisingly, such promoter hypermethyl-
ation is at least as common as the disruption of classic tumor-
suppressor genes in human cancer by mutation or deletion and
possibly more common.
In addition, promoter hypermethylation and transcriptional
repression of functionally important cancer-related genes may also
affect tumor behavior, creating an impact on clinical outcomes.
Epigenetic silencing of genes that determine tumor invasiveness,
growth patterns, and apoptosis, in particular, may dictate tumor
recurrence after treatment and affect overall survival. Because each
tumor may harbor multiple genes susceptible to promoter hyper-
methylation, individual tumors would exhibit different frequencies
of hypermethylation profile potentially predictive of a patient’s
clinical outcome.7-8
Although several reports concerning methylation of different
genes in ALL have been published, in most cases the methylation
status has been investigated for just a single gene or in a small
number of patients with short follow-up. We and others have
identified several methylated genes in ALL, including CALCA, ER,
MDR1, THBS2, MYF3, p15, p16, p73, p57, and CDH1.9-15 More-
over, methylation patterns may have clinical implications in ALL in
that CALCA, p15, p57, and p21 methylation were found to be
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associated with dismal outcome.11-15 However, it is unclear whether
methylation of these genes are prognostic because of their own
regulating functions or because they reflect a distinct pathway of
tumorigenesis in ALL, with distinct expression profiles of genes
that could influence prognosis as a consequence of the simulta-
neous methylation of multiple loci. To study this issue further, we
have examined multiple key cancer genes undergoing epigenetic
inactivation in a large set of de novo ALLs with the aim of
obtaining a map of this alteration in the disease and its possible
correlation with clinical features and patient outcome.
Patients, materials, and methods
Patients
We studied 251 consecutive patients (151 male, 100 female) who received a
diagnosis of de novo ALL between January 1990 and December 2002. The
median age at diagnosis in the study population as a whole was 14 years
(range, 0.5-82 years). Of these patients, 124 were children (median age, 5
years; range, 0.5-14 years), and 127 presented adult ALL (median age, 29
years; range, 15-82 years). Informed consent was obtained from the patient
or the patient’s guardians. Diagnosis was established according to standard
morphologic, cytochemical, and immunophenotypic criteria. Patients were
studied at the time of initial diagnosis; were risk-stratified according to the
therapeutic protocol used, which was always based on recognized prognos-
tic features (including cytogenetics); and were entered in ALL protocols of
the Programa para el estudio y tratamiento de las hemopatias malignas
(PETHEMA) Spanish study group. For statistical analyses, children were
also grouped according to the National Cancer Institute (NCI) risk-
classification criteria.16 The specific PETHEMAALL treatment protocols in
which these patients were entered included ALL-89 (between 1990 and
1993; n  51) and ALL-93 (between 1993 and 2002; n  200). The design
and results of these studies have been previously reported.17-20 Relapse
occurred in 104 patients. Forty-four patients received stem cell transplants
(14 autologous, 30 allogeneic) in the first (n  20) or second (n  24)
complete remission (CR). There are 139 patients currently alive. Clinical
characteristics of the patients are listed in Table 1.
Gene selection
High–molecular weight DNA and total RNA were prepared from mono-
nuclear marrow cells at the time of diagnosis with the use of conventional
methods. In all the cases, the diagnostic bone marrow sample contained at
least 70% blast cells. We studied 15 genes belonging to all of the molecular
pathways involved in cell immortalization and transformation: cell cycle
(p15, p16, and p57); cell adherence and metastasis process (CDH1 and
CDH13); p53 network (p14 and p73); apoptosis (TMS1, APAF-1, and
DAPK); cellular senescence (DKK-3); differentiation regulation (NES-1);
ubiquitylation (PARKIN); and main tumor-suppressor genes (LATS-1 and
PTEN). Different criteria were used for gene selection. CDH1, p73, p16,
p15, p57, NES-1, and DKK-3 were selected because of their frequent
methylation in ALL.9-11,15,21-22 CDH13, p14, TMS1, APAF-1, DAPK,
PARKIN, LATS-1, and PTEN were studied because they have been found to
be methylated in other malignancies, and their abnormal expression could
have potentially important roles in ALL23-30 (Table 2). The regions where
these genes reside are not prone to mutations, deletions, or rearrangement in
the majority of human leukemias; however, microsatellite markers from
these regions have shown that most of them are common sites for loss of
heterozygocity in ALL.31 Each of these genes possesses a CpG island in the
5 region, which is normally unmethylated in corresponding normal tissues
as expected for a typical CpG island. We and others have shown, in previous
studies for such genes in individual tumor types, that when these CpG
islands are hypermethylated in cancer cells, expression of the correspond-
ing gene is silenced and the silencing can be partially relieved by
demethylation of the promoter region.9-11,15,21-30 For all these genes, we
have analyzed at least 10 normal marrow and peripheral blood specimens,
none of which showed significant methylation.
Methylation-specific PCR (MSP)
Aberrant promoter methylation of these genes was determined by the MSP
method as reported by Herman et al.32 MSP distinguishes unmethylated
alleles of a given gene on the basis of DNA sequence alterations after
bisulfite treatment of DNA, which converts unmethylated, but not methyl-
ated, cytosines to uracils. Subsequent polymerase chain reaction (PCR)
using primers specific to sequences corresponding to either methylated or
unmethylated DNA sequences was then performed. Primer sequences of
each gene for the unmethylated and methylated reactions have been
reported elsewhere.9-11,15,21-30 “Hot-start” PCR was performed for 30
cycles; this consists of denaturation at 95°C for 1 minute, annealing at 60°C
for 1 minute, and extension at 72°C for 1 minute, followed by a final
7-minute extension for all primer sets. The products were separated by
Table 1. Clinical characteristics and outcomes of 251 patients by
methylation profile
Feature
Nonmethylated
group,
n  57, %
Methylated
group A,
n  104, %
Methylated
group B,
n  90, %
Age*
Younger than 15 years 61 46 45
Older than 15 years 39 54 55
Sex, M/F 56/44 60/40 63/37
WBC count*
Lower than 50  109/L 76 75 63
Higher than
50  109/L 24 25 37
FAB classification
L1 38 40 25
L2 50 56 64
L3 12 4 11
Blast lineage
B 88 76 64
T 12 24 36
NCI risk group
Standard 80 76 65
Poor 20 24 35
PETHEMA risk group
Standard 40 47 34
Poor 60 53 66
Treatment
PETHEMA 89 20 21 20
PETHEMA 93 80 79 80
BMT 14 17 20
Best response, CR 91 93 88
Cytogenetic/molecular
abnormalities
BCR/ABL 21 20 12
4(1;19) 4 2 2
11q23 3 3 3
c-Myc 6 3 8
7q35-14q11 6 6 5
Hyperdiploidy 9 6 5
TEL-AML1 5 16 18
None 42 39 40
Others 3 3 3
NT 1 2 2
Relapse† 17 51 59
Death‡ 28 43 61
Methylated group A indicates patients with 1, 2, or 3 methylated genes;
methylated group B, patients with more than 3 methylated genes.
WBC indicates white blood cell; FAB, French-American-British; NCI, National
Cancer Institute; PETHEMA, Programa para el estudio y tratamiento de las
hemopatias malignas; BMT, bone marrow transplantation; CR, complete remission;
and NT, not tested.
*P  .09.
†P  .0001.
‡P  .001.
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electrophoresis on 2% agarose gel. Bone marrow DNA from healthy donors
was used as negative control for methylation-specific assays. Human male
genomic DNA universally methylated for all genes (Intergen, Purchase,
NY) was used as a positive control for methylated alleles. Water blanks
were included with each assay. The presence of a clearly visible band in the
MSP using primers for the methylated alleles was considered a positive
result for methylation. This result was always confirmed by repeat MSP
assays after an independently performed bisulfite treatment. In the sporadic
cases where only faint bands were observed in both analyses, methylation
results were validated by Southern blot, sequencing, and/or association with
lack of expression assessed by reverse-transcription PCR (RT-PCR) as
appropriate. The sensitivity of this MSP was established by using totally
methylated, positive control DNA serially diluted by normal lymphocyte
DNA. MSPs with positive control DNA diluted in ratios of 1:10, 1:100, and
1:1000 produced detectable methylated bands (data not shown).
Other molecular analyses
Standard Southern blot method was employed to detect immunoglobulin
heavy-chain gene rearrangement and T-cell receptor– rearrangement. The
11q23 abnormalities were studied with the B859 probe kindly provided by
Dr G. Cimino (Rome, Italy).33 The p210BCR-ABL, p190BCR-ABL, and TEL-
AML1 fusion transcripts were detected by means of the reverse transcription–
polymerase chain reaction according to the primers and protocols estab-
lished by the European BIOMED 1 concerted action.34
Statistical analysis
For statistical purposes, ALL patients were classified into 2 different
methylation groups: nonmethylated (no methylated genes) and methylated
(at least one methylated gene). The methylated group was also divided into
2 other groups according to the number of methylated genes observed in
each individual sample: methylated group A (1 to 3 methylated genes) and
methylated group B (more than 3 methylated genes). P values for
comparisons of continuous variables in groups of patients were 2-tailed and
were based on the Wilcoxon rank sum test. P values for dichotomous
variables were based on the Fisher exact test. The remaining P values were
based on the Pearson chi-square test. Overall survival (OS) was measured
from the day of diagnosis until death from any cause and was censored only
for patients known to be alive at last contact. Disease-free survival (DFS)
was measured from the day that CR was established until either relapse or
death without relapse, and it was censored only for patients who were alive
without evidence of relapse at the last follow-up. Distributions of OS and
DFS curves were estimated by the method of Kaplan and Meier, with 95%
confidence intervals calculated by means of Greenwood’s formula. Compari-
sons of groups by OS or DFS were based on the log-rank test. Comparisons
adjusted for significant prognostic factors were based on Cox regression
models and hazard regression models. All relapse and survival data were
updated on December 2003, and all follow-up data were censored at that point.
Results
Frequency of methylation in ALL
Among 251 ALLs, the methylation frequencies (in descending
order) were as follows: 57% for NES-1, 40% for LATS-1, 37% for
CDH1, 35% for CDH13, 35% for p16, 34% for APAF-1, 33% for
DKK-3, 29% for p15, 27% for PARKIN, 20% for PTEN, 18% for
p57, 18% for p73, 13% for DAPK, 9% for TMS-1, and 8.5% for p14
(Table 3). No methylated genes were found in 57 (22.7%) of 251
patients, whereas most ALLs (194 [77.3%] of 251) had methylation
of at least 1 methylated gene (range, 1-10) (Table 3). No case was
found to have methylation of more than 10 genes. According to the
number of methylated genes observed in each individual sample,
104 patients (41.4%) were included in methylated group A (1 to 3
methylated genes) and 90 (35.9%) in methylated group B (more
than 3 methylated genes). Significant differences were found
between methylation profiles in children and adults. LATS-1
(P  .05), CDH1 (P  .05), p15 (P  .05), p57 (P  .001), and
p14 (P  .05) genes were more frequently methylated in adult ALL
than in childhood ALL (Table 3). Moreover, 82.7% of adult ALLs
showed methylated genes compared with 71.8% of childhood
ALLs (P  .03) (Table 3). Figure 1 illustrates representative
examples of the methylation patterns of the most frequently
methylated genes.
By analyzing the methylation status of 15 genes simultaneously,
we were able to study correlations between their methylation
status. Methylation of DKK-3, NES-1, PARKIN, LATS-1, PTEN,
p73, p16, p14, CDH1, CDH13, DAPK, and p15 genes were
significantly correlated (Table 4). By contrast, methylation of
TMS1 and p57 showed no significant correlation with each other or
with any of the gene groups mentioned in this paragraph.
Clinical outcome and methylation profile
As shown in Table 1, clinical and laboratory characteristics did not
differ significantly between methylation groups. Poor-risk cytoge-
netics or molecular events, risk groups according to both NCI and
Table 2. Genes studied for methylation in ALL
Gene Location Function Reference for MSP primers
NES-1 19q13 Growth and differentiation control; putative TSG Roman-Gomez et al21
LATS-1 6q23-25 TSG; G2-M cell cycle control; apoptosis regulation Hisaoka et al29
CDH1 16q22 TSG; calcium-dependent cell-cell adhesion Melki et al10
CDH13 16q24 Calcium-dependent cell-cell adhesion Roman-Gomez et al23
p16 9p21 TSG; G1-S cell cycle control Wong et al11
APAF-1 12q23 Apoptosis regulation Fu et al26
DKK-3 11p15 Wnt/catenin signaling pathway antagonist;
mortalization-related gene; putative TSG
Roman-Gomez et al22
p15 9p21 G1-S cell cycle control; putative TSG Wong et al11
PARKIN 6q25-27 E3 ubiquitin ligase; putative TSG Cesari et al28
PTEN 10q23 TSG; cell adhesion/motility; apoptosis; angiogenesis;
G1 cell cycle regulation; signal transduction
Zysman et al30
p57 11p15 G1-S cell cycle control; putative TSG Shen et al15
p73 1p36 G1-S cell cycle control; putative TSG Kawano et al9
DAPK 9q34 Apoptosis regulation Katzenellenbogen et al27
TMS-1 16p11-12 Apoptosis regulation Conway et al25
p14 9p21 Cell cycle control; apoptosis regulation Esteller et al24
MSP indicates methylation-specific polymerase chain reaction; TSG, tumor suppressor gene; E3, early region 3.
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PETHEMA classifications, good risk features (hyperdiploidy and
TEL-AML1 fusion), type of PETHEMA protocol administered, and
number of patients who received stem cell transplants were
distributed similarly among the 3 methylation groups. Separate
analysis of adult and childhood ALL patients gave the same results
as the global series.
Table 1 details the relapse history, CR rates, and mortality for
patients in the different methylation groups. CR rates of patients in
the nonmethylated, methylated A, and methylated B groups were
91%, 93%, and 88%, respectively, accounting for 91% of the
overall CR rate. This suggests that the methylation profile did not
correlate with response to remission induction therapy. However,
patients in the nonmethylated group had a lower rate of relapse than
patients in methylated groups A and B (17% versus 51% and 59%,
respectively, P  .0001). Mortality rate was also lower for the
nonmethylated group compared with methylated groups A and B
(28% versus 43% and 61%, respectively, P  .001). Similar results
were obtained in the separate analyses of children (relapse rate,
14% for nonmethylated group versus 35% and 48% for methylated
groups A and B, respectively, P  .003; mortality rate, 14% for
nonmethylated group versus 20% and 37% for methylated groups
A and B, respectively, P  .04) and adults (relapse rate, 28% for
nonmethylated group versus 67% and 68% for methylated groups
A and B, respectively, P  .002; mortality rate, 50% for nonmethy-
lated group versus 63% and 81% for methylated groups A and B,
respectively, P  .02).
We analyzed the DFS among patients who achieved CR
according to the methylation profile. Estimated DFS rates at 11
years were 75.5% and 25.6% for nonmethylated and methylated
groups, respectively (group A, 37.2%; group B, 9.4%) (P  .0001)
(Figure 2A). Among children, the 11-year DFS was 79.7% for
nonmethylated group and 36.5% for methylated group (group A,
55%; group B, 18.6%; P  .001) (Figure 2B). Among adult ALL
patients, the 11-year DFS was 66.5% for nonmethylated group and
15.6% for methylated group (group A, 20.4%; group B, 7.1%;
P  .001) (Figure 2C). The actuarial OS at 12 years calculated for
all leukemic patients was 66.1% for nonmethylated patients and
27.4% for methylated patients (group A, 45.5%; group B, 7.8%;
P  .0004) (Figure 3A). Significant differences were observed in
the actuarial OS among nonmethylated, methylated A, and methyl-
ated B groups in the separate analyses of children (78.1%, 75.1%,
and 18.1%, respectively, P  .01) (Figure 3B) and adults (46.6%,
22.1% and 4.2%, respectively, P  .05) (Figure 3C).
A multivariate analysis of potential prognostic factors (includ-
ing the type of PETHEMA protocol applied) demonstrated that
hypermethylation profile was an independent prognostic factor in
predicting DFS in the global series (P  .0001) as well as in both
childhood (P  .0001) and adult ALLs (P  .006) (Table 5).
Methylation status was also independently associated with OS in
the global series (P .003) and childhood ALL (P .02) (Table 6).
Prognostic impact of the methylation profile in
selected risk groups
To determine the prognostic impact of the methylation profile in
selected ALL groups with well-established prognostic factors, we
analyzed DFS and OS in TEL-AML1 and BCR-ABL patients and
also in patients with high white blood cell (WBC) count
( 50  109/L [ 50 000 mm3]) at diagnosis. Among TEL-AML1
children (n  44), the 8-year DFS was 87.5% for the nonmethyl-
ated group and 38% for the methylated group (P .04) (Figure 4A).
The actuarial OS at 8 years for the same patients was 100% for
nonmethylated patients and 77.4% for methylated patients (P .05)
(Figure 4A). Among BCR-ABL patients (n 47), the 6-year DFS was
67.3% for nonmethylated patients and 4.1% for methylated patients
(P .001) (Figure 4B). Estimated 7-year OS was 59.8% for nonmethy-
lated BCR-ABL patients and 0% for methylated patients (P .02)
(Figure 4B). Among ALL patients with high WBC count at diagnosis
(n 73), DFS at 9 years was 58.3% for nonmethylated patients and
Figure 1. Aberrant promoter methylation of different genes in acute lymphoblas-
tic leukemia. MW indicates molecular weight marker; ALL, acute lymphoblastic
leukemia samples; C-pos, human male genomic DNA universally methylated for all
genes (used as a positive control for methylated alleles); C-neg, healthy individual;
water, blank control without DNA added; U, unmethylated alleles; and M, methylated
alleles.
Table 3. Methylation profile in ALL
Feature Overall, % Childhood ALL, % Adult ALL, %
Methylated genes
NES-1 57 55 58
LATS-1* 40 30 47
CDH1* 37 32 42
CDH13 35 32 37
p16 35 32 36
APAF-1 34 35 34
DKK-3 33 32 33
p15* 29 20 38
PARKIN 27 30 24
PTEN 20 20 19
p57† 18 2 34
p73 18 18 18
DAPK 13 10 17
TMS-1 9 10 7
p14* 8.5 5 13
Methylation group
Nonmethylated‡ 22.7 28.2 17.3
Methylated 77.3 71.8 82.7
Group A 41.4 38.7 44.1
Group B 35.9 33.1 38.6
No. methylated genes
0* 22.7 28.2 18.1
1 9.3 8.1 9.4
2 19.9 21 18.9
3 12.7 9.7 15.7
4 10 6.5 13.4
5 10 9.7 10.2
6 5.6 6.5 4.7
7 4.8 6.5 3.1
8 2 1.6 2.4
9 1.6 1.6 1.6
10 1.6 0.8 2.4
*P  .05.
†P  .001.
‡P  .03.
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11.5% for methylated patients (P .07) (Figure 4C). No significant
difference was observed in OS in these patients.
Discussion
Epigenetic gene silencing is increasingly being recognized as a
common way in which cancer cells inactivate cancer-related
genes.4-8 Attention has focused on the methylation of regions in the
genome that might have functional significance resulting from the
extinction of gene activity. Whereas most individual cancers have
several, perhaps hundreds, of methylated genes (a phenomenon
termed CpG island methylator phenotype),35 the methylation
profiles of individual tumor types are characteristic of this type of
cancer. However, there is relatively modest information on this
profiling in ALL.13-15 Our results indicate that methylation of
multiple genes is a common phenomenon in ALL and may be the
most important way to inactivate cancer-related genes in this
disease; 77.3% of cases had at least 1 gene methylated, whereas
35.9% of cases had 4 or more genes methylated. Significant
differences were found in the methylation profiles of childhood and
Table 4. Correlations between methylation status of the different genes studied
NES DKK PARKIN APAF LATS PTEN p57 p73 p16 p14 CDH1 CDH13 DAPK TMS p15
NES — — — — — — — — — — — — — — —
DKK .0001 — — — — — — — — — — — — — —
PARKIN .0001 .0001 — — — — — — — — — — — — —
APAF NS NS NS — — — — — — — — — — — —
LATS .006 NS NS .0001 — — — — — — — — — — —
PTEN .0001 .0001 .0001 NS NS — — — — — — — — — —
p57 NS NS NS NS NS NS — — — — — — — — —
p73 NS NS NS NS NS .001 NS — — — — — — — —
p16 .001 NS NS NS NS NS NS .0001 — — — — — — —
p14 NS .005 NS NS NS NS NS NS NS — — — — — —
CDH1 .0001 .0001 .0001 NS NS .0001 NS NS NS NS — — — — —
CDH13 .0001 .0001 .0001 NS .001 .0001 NS NS NS .0001 .0001 — — — —
DAPK NS NS NS NS NS NS NS NS NS NS .0001 .0001 — — —
TMS NS NS NS NS NS NS NS NS NS NS NS NS NS — —
p15 .003 .0001 .0001 NS NS .002 .002 .004 .001 NS .0001 .0001 NS NS —
— indicates already performed; and NS, nonsignificant.
Figure 2. Kaplan-Meier survivor function for ALL patients. DFS curves according
to the methylation profile. Methylated group A indicates patients with 1 to 3
methylated genes; and methylated group B, patients with more than 3 methylated
genes. (A) All patients enrolled in this study. (B) Childhood ALL. (C) Adult ALL.
Figure 3. Kaplan-Meier survivor function for ALL patients. OS curves according
to the methylation profile. Methylated A indicates patients with 1 to 3 methylated
genes; and methylated B, patients with more than 3 methylated genes. (A) All patients
enrolled in this study. (B) Childhood ALL. (C) Adult ALL.
2496 ROMAN-GOMEZ et al BLOOD, 15 OCTOBER 2004  VOLUME 104, NUMBER 8
adult ALLs, suggesting that methylation status in ALL is age
related. Adult ALL patients showed more frequent methylation of
LATS-1, CDH1, p15, p57, and p14 genes and also a higher number
of simultaneously methylated genes than childhood ALL patients.
It is well known that prognosis of children with ALL is significantly
superior to that of adults, even if they are matched for poor
prognosis features; our results suggest that this different epigenetic
map may have a role in explaining the prognostic differences in the
2 age groups. Furthermore, methylation of several of the genes
analyzed here was strongly correlated, suggesting that CpG island
methylation is related to specific methylation defects in subsets
of ALLs, rather than that methylation of each individual island
represents a random event followed by selection for the af-
fected cell.
Our data also show that the methylation in human ALL cells can
participate in the inactivation of 3 key cellular pathways:
1. growth-deregulating events comprising events that target the
principal late-G1 cell cycle checkpoint either directly (p15, p16,
and p57 inactivation) or indirectly (p73, PTEN, and NES-1
inactivation) and events that regulate the G2-M transition down-
regulating CDC2/cyclin A kinase activity (LATS-1) and those that
antagonize the WNT/beta-catenin oncogenic signaling pathway
(DKK-3);
2. the apoptotic program through inactivation of p14, TMS1,
APAF-1, and DAPK; and
3. the cell-cell adhesion by the inactivation of some members of
the cadherin family (CDH13 and CDH1), which are more than
simply a “sticky molecular complex” because they have the ability
to inhibit cell proliferation by the up-regulation of p27 (another G1
checkpoint gene) and because their down-regulation also interferes
with apoptotic signals putting the affected cell into a state of de
facto anoikis.36
All these abnormalities are not surprising. Beneath the complex-
ity and idiopathy of every cancer lies a limited number of
“mission-critical” events that have propelled the tumor cell and its
progeny into uncontrolled expansion and invasion. One of these is
deregulated cell proliferation, which, together with the compensa-
tory suppression of apoptosis needed to support it, provides a
minimal “platform” necessary to support further neoplastic progres-
sion.37 Our data show that in ALL this common platform can be
achieved by a methylation mechanism. Interestingly, although
genetic abnormalities of key tumor-suppressor genes such as RB
and, especially, p53 are the most common molecular lesions in
human cancer,38 they are relatively less frequent in de novo ALL.3
In view of our results, one hypothesis is that the methylation of
Table 5. Multivariate Cox model for disease-free survival
Feature Univariate analysis P Multivariate analysis P
Global series
Methylation profile  .0001  .0001
WBC count higher than
50  109/L .0002 .002
BCR-ABL positivity .004 .01
T phenotype .03 —
Age older than 15 years .007 —
PETHEMA poor risk .04 —
Childhood ALL
Methylation profile .0001 .0001
PETHEMA poor risk .05 .05
WBC count higher than
50  109/L .05 —
NCI poor risk .05 —
Adult ALL
BCR-ABL positivity  .0001 .001
Methylation profile .003 .006
WBC higher than 50  109/L .0002 .02
— indicates not significant.
Table 6. Multivariate Cox model for overall survival
Feature Univariate analysis P Multivariate analysis P
Global series
WBC count higher than
50  109/L  .0001  .0001
Methylation profile .0005 .003
PETHEMA poor risk  .0001 .01
Age older than 15 years  .0001 .05
BCR-ABL positivity .0003 —
T phenotype .005 —
Childhood ALL
T phenotype .005 .005
Methylation profile .03 .02
WBC count higher than
50  109/L .05 —
NCI poor risk .05 —
Adult ALL
WBC count higher than
50  109/L .0001 .0001
BCR-ABL positivity .001 .05
Methylation profile .03 —
See Table 5 footnote for abbreviations.
Figure 4. Kaplan-Meier survivor function for selected prognostic groups of ALL
patients. DFS and OS curves according to the methylation profile. (A) TEL-AML1
ALL patients. (B) BCR-ABL ALL patients. (C) Patients with high WBC count at
diagnosis.
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cytosine nucleotides in ALL cells can help inactivate (1) tumor-
suppressive apoptotic or growth-arresting responses by deregula-
tion of the cyclin-dependent kinases that phosphorylate and
functionally inactive retinoblastoma (RB) protein (at the p15, p16,
and p57 level) and either upstream (at p14 or DAPK) or down-
stream (APAF-1) of p53 and also (2) p73, which encodes for a
protein that is both structurally and functionally homologous to the
p53 protein.39 This implies that in ALL too there is a strong
selection for tumor cells to lose critical tumor-suppressor gene
functions (not only p53 and RB but also LATS-1 and PTEN) but, in
this case, indirectly through an alternative epigenetic way.
In this study, we have shown that aberrant methylation of
CpG islands is quantitatively different in individual tumors
within the same tumor type and that this patient-specific
methylation profile provides important prognostic information
in ALL patients. The presence in individual tumors of multiple
epigenetic events that affect each of the pathways we have
discussed is a factor of poor prognosis in both childhood and
adult ALL. Patients with methylation of 4 or more genes had a
poorer DFS and OS than patients with 3 or fewer methylated
genes or patients lacking promoter hypermethylation. Multivar-
iate analysis confirmed that methylation profile was associated
with a shorter DFS and OS. Moreover, methylation status was
able to redefine the prognosis of selected ALL groups with
well-established prognostic features. Lack of promoter methyl-
ation improved the generally poor outcome of patients present-
ing Philadelphia chromosome or high WBC count at diagnosis,
whereas the presence of methylation worsened the generally
good outcome of TEL-AML1 patients. Therefore, methylation
profiling in ALL could have important clinical implications,
complementing standard immunophenotypic, cytogenetic, and
molecular studies for guiding the selection of therapy and also
providing a basis for developing novel therapies, such as
demethylation treatment.
In summary, our results indicate that simultaneously aberrant
methylation affecting key molecular pathways is a common
phenomenon in ALL. The methylation profile seems to be an
important factor in predicting the clinical outcome of ALL patients.
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